Susana Fraile
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Chemotherapy-induced cardiotoxicity and mitigation, PARP inhibition in cancer therapy, Peptidase Inhibition and Analysis, Archaeological and Geological Studies
Most-Cited Works
- → The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin(2015)98 cited
- → Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease(2014)85 cited
- → Transcription Factors Sp1 and p73 Control the Expression of the Proapoptotic Protein NOXA in the Response of Testicular Embryonal Carcinoma Cells to Cisplatin(2012)48 cited
- → Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors(2013)20 cited
- → El Cerro de los Batallones: un caso práctico de actuación paleontológica de carácter preventivo(2003)3 cited
- → Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin(2017)1 cited
- Study of genetic factors determining the heterogeneous activation of signaling pathways associated with cardiac pathophysiology and their contribution to the individual susceptibility to cardiotoxicity caused by chemotherapy(2016)
- → Datasets related to a study aimed to identify genetic markers of CDA by subphenotypes associated with cardiotoxicity(2021)
- → Identification of QTL associated with cardiotoxicity due to anthracyclines and taxanes and DNA damage response(2017)
- PreclinicalActivityoftheOralProteasomeInhibitorMLN9708 in Myeloma Bone Disease(2014)